Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024?

The updated guidelines on the pillars for heart failure with reduced ejection fraction (HFrEF) and acute decompensation improved patient outcomes, but continuous efforts are made to uncover new evidence and develop novel treatments. This review aims to examine limitations of current therapies and the potential impact of emerging treatments.